Elevated Galectin-3 Levels in the Serum of Patients With Alzheimer's Disease

In this study, we found significantly increased Gal-3 serum levels in patients with AD compared to control participants (P = .017). There was no significant difference between patients with mild cognitive impairment (MCI) and healthy controls (P = .143) or between patients with AD and MCI (P = .688). The degree of cognitive impairment, as measured by the Mini-Mental Status Examination score, was found to have a significant correlation with the Gal-3 serum levels in all patients and healthy controls. These data suggest that Gal-3 potentially plays a role in the neuropathogenesis of AD. The Gal-3 found in serum could be a potential candidate for a biomarker panel for AD diagnosis.
Source: American Journal of Alzheimer's Disease and Other Dementias - Category: Geriatrics Authors: Tags: Research Source Type: research